INTERVIEW: Can St Jude-backed Micell absorb share from other DES players?
This article was originally published in Clinica
Executive Summary
When assessing the investment potential of start-ups, it always helps to look at who the company’s backers are to separate the wheat from the chaff. In the case of drug-eluting stent specialist Micell Technologies, having a cardiology heavyweight like St Jude Medical among its roll call of investors would have undoubtedly given it some kudos.